Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Kswdeluxon Dec 09, 2022 11:23pm
165 Views
Post# 35163188

RE:Positive results once again

RE:Positive results once again

westcoast1000 wrote: ONCY and pela continue to produce positive results.

Hence, there is nothing in the way now, and no reason to doubt we will be hearing positive news on Bracelet in about three months or so.

What hurts many investors here is the disconnect with the share price.

I do not pay any real attention to the s/p. With other companies our results would matter a lot to the market, but because our price is already so disproportionately low, investors are staying out due to what they see as ongoing uncertainty.

Someone had a good comment on stocktwits. It is almost as if this company is going for a slam dunk on a registration trial before applying. To me, that makes sense. This is a one molecule company. pela is its only product. They are nurturing it through the approval process. That is why they have waited 5 years on the fast track designation for mBC.

But we have basically put every brick in place in the wall.

Now we wait for big pharma to buy what we have to offer.





 

 I totally agree! 

<< Previous
Bullboard Posts
Next >>